INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
Public company

DYNDyne Therapeutics, Inc.

CIK 0001818794

EDGAR filingsOpen in network
Disclosed transactions8
Buys / sells0 / 6
Max Insider Score10
Connections4with evidence

DYN · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
5
KD
Kerr DouglasHead of R&D and CMO
DYNDyne Therapeutics, Inc.
Grant or award
A—
8,000 sh
Oct 20, 2026Oct 22, 2026
traded Oct 20, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Lobbied forevidence
    W STRATEGIES, LLCLDA RR 2026 second quarter · Health issues · Aug 26, 2026
  • ← Insider ofevidence
    Friedl-Naderer JohannaChief Commercial Officer · Aug 17, 2026
  • ← Insider ofevidence
    Kerr DouglasChief Medical Officer · Aug 17, 2026
5
KD
Kerr DouglasHead of R&D and CMO
DYNDyne Therapeutics, Inc.
Grant or award
A
—
12.0K sh
Oct 20, 2026
Oct 22, 2026
traded Oct 20, 2026
+2d
SEC FORM 4

Evidence

9
KD
Kerr DouglasChief Medical Officer
DYNDyne Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$91K
3,745 sh
Sep 4, 2026Sep 8, 2026
traded Sep 4, 2026
+4dSEC FORM 4

Evidence

6
KD
Kerr DouglasChief Medical Officer
DYNDyne Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$24K
1,290 sh
Sep 8, 2026Sep 8, 2026
traded Sep 8, 2026
+0dSEC FORM 4

Evidence

6
FJ
Friedl-Naderer JohannaChief Commercial Officer
DYNDyne Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$3,493
185 sh
Sep 8, 2026Sep 8, 2026
traded Sep 8, 2026
+0dSEC FORM 4

Evidence

6
FJ
Friedl-Naderer JohannaChief Commercial Officer
DYNDyne Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$22K
900 sh
Sep 4, 2026Sep 8, 2026
traded Sep 4, 2026
+4dSEC FORM 4

Evidence

10
FJ
Friedl-Naderer JohannaChief Commercial Officer
DYNDyne Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$5,939
226 sh
Aug 13, 2026Aug 17, 2026
traded Aug 13, 2026
+4dSEC FORM 4

Evidence

10
KD
Kerr DouglasChief Medical Officer
DYNDyne Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$41K
1,556 sh
Aug 13, 2026Aug 17, 2026
traded Aug 13, 2026
+4dSEC FORM 4

Evidence

Lobbying

$40K reported · de-duplicated
2026 Q2 $40K via firms
  • W STRATEGIES, LLC—2026 Q2 · posted Aug 26, 2026 · Health issues
  • W STRATEGIES, LLC$40K2026 Q2 · posted Aug 26, 2026 · Health issues

Connected PAC contributions

FEC · direct to members

No contributions from a PAC connected to this company.